23andMe Granted New FDA Clearance to Report Additional BRCA Variants

23andMe Holding Co. (23andMe), a leading human genetics and biopharmaceutical company, Friday announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*.